Optimization of glycoprotein IIb/IIIa blockade during percutaneous coronary interventions: Insights from TARGET after 1 year

Medicine and Dentistry

• Abciximab 100%
• Acute Coronary Syndrome 16%
• Antiplatelet 16%
• Clopidogrel 16%
• Death 16%
• Diabetes Mellitus 50%
• Fibrinogen Receptor 100%
• Fibrinogen Receptor Antagonist 16%
• Health Care Cost 16%
• Heart Muscle Ischemia 16%
• Integrin 16%
• Intervention Trial 16%
• Introspection 100%
• Life 16%
• Myocardial Infarction 16%
• Patient 83%
• Percutaneous Coronary Intervention 100%
• Platelet Glycoprotein 16%
• Restenosis 16%
• Survival 16%
• Target Vessel Revascularization 16%
• Tirofiban 100%
• Vitronectin 16%